Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 509


Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2013 Jun 19;309(23):2480-8. doi: 10.1001/jama.2013.6959.


Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2014 Apr 23-30;311(16):1632-40. doi: 10.1001/jama.2014.3203.


Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.

Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, Cook A, Campo-Bustillo I, Khatri P, Bhatt DL, Fonarow GC, Sacco RL, Schwamm LH.

JAMA Neurol. 2015 Apr;72(4):423-31. doi: 10.1001/jamaneurol.2014.4354.


Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.

Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED.

JAMA. 2012 Jun 27;307(24):2600-8. doi: 10.1001/jama.2012.6756.


Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.

Xian Y, Federspiel JJ, Grau-Sepulveda M, Hernandez AF, Schwamm LH, Bhatt DL, Smith EE, Reeves MJ, Thomas L, Webb L, Bettger JP, Laskowitz DT, Fonarow GC, Peterson ED.

JAMA Neurol. 2016 Jan;73(1):50-9. doi: 10.1001/jamaneurol.2015.3106.


Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population.

Kim JT, Fonarow GC, Smith EE, Reeves MJ, Navalkele DD, Grotta JC, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Schwamm LH, Saver JL.

Circulation. 2017 Jan 10;135(2):128-139. doi: 10.1161/CIRCULATIONAHA.116.023336. Epub 2016 Nov 4.


Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?

Martin-Schild S, Morales MM, Khaja AM, Barreto AD, Hallevi H, Abraham A, Sline MR, Jones E, Grotta JC, Savitz SI.

J Emerg Med. 2011 Aug;41(2):135-41. doi: 10.1016/j.jemermed.2008.10.018. Epub 2009 Mar 9.


Hospital variation in thrombolysis times among patients with acute ischemic stroke: the contributions of door-to-imaging time and imaging-to-needle time.

Sauser K, Levine DA, Nickles AV, Reeves MJ.

JAMA Neurol. 2014 Sep;71(9):1155-61. doi: 10.1001/jamaneurol.2014.1528.


Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.

Anaissie JE, Monlezun DJ, Siegler JE, Waring ED, Dowell LN, Samai AA, George AJ, Kimbrough T, Berthaud J, Martin-Schild S.

J Stroke Cerebrovasc Dis. 2016 Nov;25(11):2603-2609. doi: 10.1016/j.jstrokecerebrovasdis.2016.06.044. Epub 2016 Jul 28.


Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.

Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV.

Arch Neurol. 2001 Dec;58(12):2009-13.


Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.

Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):543-9. doi: 10.1161/CIRCOUTCOMES.111.000303.


Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age.

Arora R, Salamon E, Katz JM, Cox M, Saver JL, Bhatt DL, Fonarow GC, Peterson ED, Smith EE, Schwamm LH, Xian Y, Libman RB.

Stroke. 2016 Sep;47(9):2347-54. doi: 10.1161/STROKEAHA.116.012241. Epub 2016 Aug 4.


Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients.

Busl KM, Nogueira RG, Yoo AJ, Hirsch JA, Schwamm LH, Rost NS.

J Stroke Cerebrovasc Dis. 2013 Aug;22(6):718-24. doi: 10.1016/j.jstrokecerebrovasdis.2011.11.005. Epub 2011 Dec 17.


Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore.

Sharma VK, Tsivgoulis G, Tan JH, Wong LY, Ong BK, Chan BP, Teoh HL.

J Stroke Cerebrovasc Dis. 2010 Nov-Dec;19(6):424-30. doi: 10.1016/j.jstrokecerebrovasdis.2009.07.015.


Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke.

Ovbiagele B, Smith EE, Schwamm LH, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):929-35. doi: 10.1161/CIRCOUTCOMES.114.001144. Epub 2014 Sep 23.


Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.

Messé SR, Khatri P, Reeves MJ, Smith EE, Saver JL, Bhatt DL, Grau-Sepulveda MV, Cox M, Peterson ED, Fonarow GC, Schwamm LH.

Neurology. 2016 Oct 11;87(15):1565-1574. Epub 2016 Sep 14.


Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?

Hassan AE, Chaudhry SA, Jani V, Grigoryan M, Khan AA, Adil MM, Qureshi AI.

J Stroke Cerebrovasc Dis. 2013 May;22(4):545-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.022. Epub 2013 Feb 28.


Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.

Matsuo R, Kamouchi M, Ago T, Hata J, Shono Y, Kuroda J, Wakisaka Y, Sugimori H, Kitazono T; FSR investigators.

Geriatr Gerontol Int. 2014 Oct;14(4):954-9. doi: 10.1111/ggi.12205. Epub 2013 Dec 9.


Supplemental Content

Support Center